Betta Pharmaceuticals gets four oncology drugs added to national medical insurance catalog

Betta Pharmaceuticals announced today that four of its oncology products—Icotinib Hydrochloride Tablets (Conmana®), Ensartinib Hydrochloride Capsules (Bemina®), Befotnib Mesylate Capsules (Saimenona®), and Voronib Tablets (Vimena®)—have been successfully added to the National Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalogue (2025). This inclusion, effective from January 1, 2026, is expected to enhance product accessibility and positively impact sales.

The products encompass various classifications, including epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and other protein kinase inhibitors, targeting advanced or metastatic non-small cell lung cancer (NSCLC) and advanced renal cell carcinoma (RCC). Conmana is approved for multiple indications, including first-line treatment and adjuvant therapy for EGFR mutation-positive NSCLC, while Bemina targets ALK-positive NSCLC.

Saimenona is indicated for EGFR T790M mutation-positive NSCLC, and Vimena for advanced RCC following prior tyrosine kinase inhibitor treatment failure. Additionally, the company's Bevazimab Injection (Beianjin®) is also listed in the national medical insurance drug catalogue. Investors are cautioned to manage investment risks.